Aquestive Therapeutics
AQST
36 hedge funds and large institutions have $90.5M invested in Aquestive Therapeutics in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 18 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
6.88% less ownership
Funds ownership: 64.5% → 57.62% (-6.9%)
18% less funds holding
Funds holding: 44 → 36 (-8)
39% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 18
68% less capital invested
Capital invested by funds: $282M → $90.5M (-$191M)
Top Buyers
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$2.16M |
| 2 |
BlackRock
New York
|
+$2.15M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.52M |
| 4 |
Squarepoint
New York
|
+$377K |
| 5 |
State Street
Boston,
Massachusetts
|
+$351K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Barclays
London,
United Kingdom
| – | -$34K | -1,956 | Closed |
|
52
UBS Group
Zurich,
Switzerland
| – | -$23K | -1,325 | Closed |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$9K | -521 | Closed |
|
|
PHK
54
Point72 Hong Kong
Hong Kong
| – | -$5K | -311 | Closed |
|
AQST Hedge Fund Activity: Q4 2018 in Review
36 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q4 2018, worth a combined $90.5M — down 68% from $282M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of AQST and 11 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Massachusetts Financial Services, adding an estimated $2.16M. The largest seller was Crestline Management, exiting entirely with an estimated $201M sold.
- 36 institutional investors held Aquestive Therapeutics (AQST) as of Q4 2018, down from 44 in Q3 2018.
- Funds reported $90.5M of Aquestive Therapeutics stock for Q4 2018, down 68% quarter-over-quarter.
- 11 funds opened new Aquestive Therapeutics positions in Q4 2018 and 18 closed out, a net change of -7 holders.
- The largest Aquestive Therapeutics buyer in Q4 2018 was Massachusetts Financial Services, an estimated $2.16M added.
- The largest Aquestive Therapeutics seller in Q4 2018 was Crestline Management, an estimated $201M sold.
Based on aggregated 13F filings for Q4 2018.